The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corp. (BAC), ...

Sage Therapeutics (NASDAQ:SAGE) stock drops as Bank of America issues an Underperform rating citing an end to Biogen's (BIIB) ...

Bank of America started coverage on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a report released on Tuesday. The brokerage issued an underperform rating and a $5.00 target price on the ...

BofA resumed coverage of Sage Therapeutics (SAGE) with an Underperform rating and $5 price target. The impact of Biogen’s (BIIB) unsolicited ...

Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...

Sage Therapeutics has said it will cut its headcount by 40% in the wake of the narrower-than-hoped approval of its flagship antidepressant Zurzuvae by the FDA, with two of the company's founders ...

The GABAA receptor positive allosteric modulator will be sold as Zurzuvae for PPD, which affects women after childbirth and can make it hard for new mothers to bond with their newborns.

Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of ...

After hours: March 11 at 4:26:13 PM EDT Loading Chart for SAGE ...